CF
TTPH

Centaurus Financial’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Centaurus Financial’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-100
Closed -$7K – 2329
2018
Q2 		$7K Buy
+100
New +$7.06K ﹤0.01% 1705

Other funds holding TTPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Centaurus Financial's TTPH Position: Q3 2018 in Review

Centaurus Financial sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2018, closing a stake of 100 shares — an estimated $7K sold.

Centaurus Financial first reported a position in TTPH in Q2 2018 and held it in 1 quarter. The position peaked at $7K in Q2 2018. 92 funds tracked by Wall St. Rank hold TTPH as of Q3 2018.

  • Centaurus Financial reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Centaurus Financial sold 100 Tetraphase Pharmaceuticals, Inc. shares in Q3 2018, an estimated $7K.
  • Centaurus Financial first reported a position in Tetraphase Pharmaceuticals, Inc. in Q2 2018 and held it in 1 quarter.
  • Centaurus Financial's Tetraphase Pharmaceuticals, Inc. position peaked at $7K in Q2 2018.
  • 92 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2018.

Based on Centaurus Financial's 13F filing for Q3 2018, filed 5 Nov 2018.